RenMab mice have complete human antibody heavy and light chain variable regions in situ replaced for the development of fully human monoclonal antibodies with high diversity, high affinity, and low immunogenicity.
The binding affinity of RenMab derived antibodies is comparable to antibodies generated from wild - type mouse and chimeric antibodies.
1. Spleen B Cell Development
Frequently Asked Questions (FAQs) About RenMab
1. What is RenMab®, and how does it generate fully human antibodies?
RenMab® is Biocytogen’s fully human monoclonal antibody discovery platform within the RenMice® family. Powered by our proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE™) technology, RenMab® replaces mouse antibody genes with their human counterparts in situ. Natural heavy-light chain pairing and affinity maturation in vivo enable the discovery of diverse high-affinity fully human monoclonal antibodies with favorable developability.
2. Why are fully human antibodies valuable for therapeutic development?
Fully human antibodies can help reduce risk of immunogenicity associated with non-human sequences, including anti-drug antibody (ADA) formation. They also eliminate the need for downstream humanization, providing a direct route to therapeutic candidates while avoiding potential changes in binding or function during humanization.
3. What is the genetic design strategy behind the RenMab® platform?
Unlike random gene insertion approach, RenMab® uses precise in situ gene replacement to replace mouse heavy-chain V(D)J and kappa light-chain variable region loci with their human counterparts, creating a comprehensive human antibody variable-region repertoire. Our platform preserves native regulatory control to support B-cell development, natural antibody gene recombination and immune-driven antibody discovery.
4. What other antibody discovery platforms and formats does Biocytogen offer?
Beyond RenMab® for fully human monoclonal antibody discovery, Biocytogen offers: